Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P00750 (PLA)
 16,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The authors found twofold higher activity of the plasminogen activator (PA) in the thyroid tissue of patients with Graves-Basedow disease as compared to the activity in tissue of the hyperthyroid nodular and neutral goitres. This activity mainly depends on the activator of urokinase type which is included in all kinds of goitre in similar amounts i.e. about 90%. The quantitative evaluation of the activity of the urokinase inhibitor points to its marked concentration in the tissue of both hyperthyroid and neutral goitres. Taking into consideration the above data and the higher fibrinolytic activity of the blood serum in the thyroid veins than in the peripheral veins it may be assumed that there is a serious danger of excessive activation of fibrinolysis after a subtotal resection of the thyroid gland.
 ...
PMID:Tissue plasminogen activator (PA) and urokinase inhibitor in the tissue of neutral and hyperthyroid goitre. 169 81

The aim of the study was to evaluate function of endothelial cells in the patients with hyperthyrosis before thyrostatic treatment on the base of known markers of endothelial disturbances: von Willebrand factor and tissue plasminogen activator. The study was performed in the 36 patients aged 20-60 (means 36.7) years suffering from Graves disease and in 17 patients with hyperthyrotic goitre aged 30-59 (means 45.8). The control group consisted of 40 healthy volunteers. In the blood plasma concentration of tissue plasminogen activator (t-PA) and von Willebrand factor (vWF) antigen were determined with enzyme-linked immunoassay (ELISA). In patients with hyperthyroidism significantly increased antigen concentration of both studied parameters were observed. It seems that increased concentration of t-PA and vWF antigen in the blood of hyperthyrotic patients was the result of the release of them from injured thyroid gland by disease or of stimulating effect of thyroid hormones on the t-PA and vWF synthesis in the endothelial cells.
 ...
PMID:[Markers of endothelial stimulation in hyperthyroidism]. 1033 77

Several papers concerning abnormalities of blood coagulation and fibrinolysis during hyperthyroidism, have been published. Increased von Willebrand Factor (vWF) activity and high fibrinogen levels have been reported. However, there is controversy concerning the presence of a hypercoagulable state in hyperthyroidism. We investigated various hemostatic parameters in 41 hyperthyroid patients and compared them to 20 euthyroid controls. Prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factors V, VII, VIII, IX and X activities, vWF, antithrombin III (AT III), protein C, protein S, tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor-1 (PAI-1), as well as common lipid variables, were measured. The relationships between serum thyroid hormones and these hemostatic parameters were examined. Compared with control subjects, fibrinogen, factor IX, vWF, AT III and PAI-1 were significantly increased in patients (p<0.05, p<0.0001, p<0.05, p<0.01 and p<0.0001; respectively), whereas factor X and t-PA were decreased (p<0.05). We showed that free T4 (FT3) levels were correlated with factor VIII activity (r=0.35, p<0.05). FT4, FT3 and TSH did not correlate with fibrinogen, vWF, AT III, t-PA, or PAI-1. AT III was inversely correlated with factor VII activity (r=-0.48, p<0.01). Protein C and S were correlated with vWF levels (r=0.58, p<0.0001; r=0.55, p<0.0001, respectively). Protein C was inversely correlated with t-PA (r=-0.39, p<0.01). There was a negative correlation between triglycerides, LDL-C and F X (r=-0.45, p<0.05; r=-64, p<0.01, respectively). Mean platelet volume (MPV) was correlated with anti-thyroid peroxidase (TPO) antibodies (in Graves'disease) and F IX activity (r=0.57, p<0.05 and r=0.39, p<0.05; respectively). We found important differences in the coagulatory /fibrinolytic parameters between the hyperthyroid patients and healthy controls. Hyperthyroid patients may experience vascular endothelial dysfunction and decreased fibrinolytic activity in blood. This endothelial activation may represent a situation with a higher thromboembolic potential.
 ...
PMID:Blood coagulation and fibrinolysis in patients with hyperthyroidism. 1203 Jun 6

Various coagulation abnormalities occur in thyroid disorders and its range may vary from subclinical laboratory abnormalities to clinically significant disorders of coagulation. Tissue factor pathway inhibitor (TFPI), which inhibits the initial reaction of tissue factor mediated coagulation pathway, is reported to be increased in patients with Graves disease (GD) in one study. Hyperthyroid (n=10), hypothyroid (n=10) and subclinical hypothyroid (n=10) patients and control cases (n=16) were evaluated for free and total tissue factor pathway inhibitor (tTFPI), plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) levels in disease and euthyroid states. Free TFPI levels were significantly higher in hyperthyroid patients compared with the control group and subclinic hypothyroid patients (p<0.001), but not with hypothyroid patients (p>0.05). After the euthyroid state was obtained in the hyperthyroid group, the levels of total TFPI (p<0.05), free TFPI (fTFPI) (p<0.005), t-PA (p<0.005) and PAI-1 (p<0.02) decreased significantly. In hyperthyroid patients, there was a strong correlation between thyroid functions and free TFPI levels. In conclusion, we hypothesize that coagulation abnormalities seen in thyroid disorders cannot be explained directly with the impaired fibrinolytic activity but also with the elevated fTFPI levels. Both increased plasma fTFPI and PAI-1 levels could be markers of the peripheral activity of thyroid hormones.
 ...
PMID:Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders. 1451 89